RESULTS OF ORGAN-SPARING THERAPY FOR MUSCLE-INVASIVE BLADDER CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper presents the results of organ-sparing therapy in 304 patients with muscle-invasive bladder cancer in whom cystectomy was contraindicated.

Full Text

Restricted Access

About the authors

Yu. Gumenetskaya

Medical Radiological Research Center

Email: GumenetskayYul@yandex.ru
Candidate of Medical Sciences Obninsk

A. Popov

Medical Radiological Research Center

Candidate of Medical Sciences Obninsk

O. Karyakin

Medical Radiological Research Center

Professor MD Obninsk

References

  1. Каприн А.Д., Добровольская Н.Ю., Шестаков А.В. и др. Результаты комплексного и комбинированного лечения инвазивного рака мочевого пузыря // Вестник Российского научного центра рентгенорадиологии Минздрава России. - 2011; 2: 20.
  2. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году / М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2013; 232 с.
  3. Русаков И.Г., Теплов А.А., Перепечин Д.В. и др. Рак мочевого пузыря. Онкология. Нац. рук-во. Под ред. В.И. Чиссова, М.И. Давыдова / М.: ГЭОТАР-Медиа, 2008; с. 777-88.
  4. Чернышев И.В., Перепечин Д.В., Ульбашев А.М. Химиотерапия в комбинированном лечении местно-распространенного рака мочевого пузыря // Вестник РНЦРР МЗ РФ. -2012; 12: 10.
  5. Abazeed M., Efstathiou J., Heney N. et al. Bladder preservation strategies for invasive bladder cancer. Comprehensive textbook of genitourinary oncology. Ed. P. Scardino, W. Linehan, M. Zelefsky et al. Philadelphia: Wolters Kluwer, 2011; p. 451-69.
  6. Balar A., Bajorin D., Milowsky M. Management of invasive bladder cancer in patients who are not candidates for or decline cystectomy // Ther. Adv. Urol. -2011; 3 (3): 107-17.
  7. Caffo O., Veccia A., Fellin G. et al. Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature // Crit. Rev. Oncol. Hematol. -2013; 86 (2): 176-90.
  8. Efstathiou J., Bae K., Shipley W. et al. Late pelvis toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06 // J. Clin. Oncol. - 2009; 27 (25): 4051-61.
  9. Efstathiou J., Spiegel D., Shipley W. et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience // Eur. Urol. - 2012; 61 (4): 705-11.
  10. Foster W., Lee B., Speight J. Bladder cancer // Handbook of Evidence-Based Radiation Oncology. Second Edition. Ed. E.K. Hansen, M. Roach III / USA: Springer, 2010; p. 419-29.
  11. Krause F., Walter B., Ott O. et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment // Anticancer Res. - 2011; 31 (3): 985-90.
  12. Lagrange J., Bascoul-Mollevi C., Geoffrois L. et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015) // Int. J. Radiat. Oncol. Biol. Phys. - 2011; 79 (1): 172-8.
  13. Rene N., Cury F., Souhami L. Conservative treatment of invasive bladder cancer // Cur. Oncol. - 2009; 16 (4): 36-47.
  14. Rodel C., Grabenbauer G., Kuhn R. еt al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results [comment] // J. Clin. Oncol. - 2002; 20 (14): 3061-71.
  15. Zapatero A., Martin de V., Arellano R. et al. Updated results of bladder-sparing trimodality approach for invasive bladder cancer // Urol. Oncol. - 2010; 28 (4): 368-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Russkiy Vrach Publishing House